Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Chinese Journal of Cancer Research
Published in: Chinese Journal of Cancer Research 4/2011

01-12-2011 | Original Article

Expressions of thymidylate synthase, thymidine phosphorylase, class III β-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin

Authors: Ming Lu, Jing Gao, Xi-cheng Wang, Lin Shen

Published in: Chinese Journal of Cancer Research | Issue 4/2011

Login to get access
Metadata
Title
Expressions of thymidylate synthase, thymidine phosphorylase, class III β-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin
Authors
Ming Lu
Jing Gao
Xi-cheng Wang
Lin Shen
Publication date
01-12-2011
Publisher
Chinese Anti-Cancer Association
Published in
Chinese Journal of Cancer Research / Issue 4/2011
Print ISSN: 1000-9604
Electronic ISSN: 1993-0631
DOI
https://doi.org/10.1007/s11670-011-0288-8

Other articles of this Issue 4/2011

Chinese Journal of Cancer Research 4/2011 Go to the issue

Original Article

Expression and distribution characteristics of human ortholog of mammalian enabled (hMena) in glioma

Original Article

Radiofrequency ablation for postoperative recurrences of intrahepatic cholangiocarcinoma

Original Article

Mast cells in adjacent normal colon mucosa rather than those in invasive margin are related to progression of colon cancer

Original Article

Prognostic value of promoter hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (p16/MTS1) in prostate cancer

Original Article

Dosimetry comparison between volumetric modulated arc therapy with RapidArc and fixed field dynamic IMRT for local-regionally advanced nasopharyngeal carcinoma

Erratum

Erratum to: Src Is dephosphorylated at tyrosine 530 in human colon carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits